Catabasis Pharma (CATB) Tops Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Catabasis Pharmaceuticals Reports Third Quarter 2019 Financial Results and Reviews Business Progress
November 7, 2019 8:05 AM EST-- Edasalonexent Global Phase 3 PolarisDMD Trial in Duchenne Muscular Dystrophy Fully Enrolled with Top-Line Results Expected in Q4 2020 --
-- Conference Call and Webcast Today at 8:30am ET --
BOSTON--(BUSINESS WIRE)-- Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter... More
